NEW YORK, August 13, 2020 / PRNewswire / – Pomerantz LLP is investigating claims on behalf of investors in Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO). It is recommended that these investors get in touch Robert S. Willoughby at the (Email protected) or 888-476-6529, ext. 7980.
The investigation concerns whether Mesoblast and any of its officers and / or directors have committed securities fraud or other illegal business practices.
(Click here for information on how to participate in the class action.)
On August 11, 2020The US Food and Drug Administration ("FDA") published informational materials for the August 13, 2020 FDA Oncological Drugs Advisory Committee meeting at which the FDA will review and discuss Mesoblast's marketing application for Ryoncil (Remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. The FDA briefing documents stated that it was "unclear" whether the study results supporting the use of mesoblast are "relevant" to the proposed indication for use.
In the news, Mesoblast's share price fell $ 6.09 per share or 34.96% to close at $ 11.33 per share on August 11, 2020.
The Pomerantz company with offices in new York, Chicago, los Angeles, and Paris is recognized as a leader in corporate, securities and antitrust litigation. Established by the late Abraham L. PomerantzPomerantz Company, known as the dean of class action, pioneered class action lawsuits. Today, more than 80 years later, the Pomerantz company continues its tradition and fights for the rights of victims of securities fraud, fiduciary violations and corporate misconduct. The company has reclaimed numerous millions of dollars in damages on behalf of class members. See www.pomerantzlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
SOURCE Pomerantz LLP